Intestinal lipoprotein overproduction in insulin-resistant states

Current Opinion in Lipidology

Volumn 19, Issue 3, 2008, Pages 221-228

  Adeli, Khosrow ^a,b   Lewis, Gary F ^b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apolipoprotein B48; Dyslipidemia; Insulin resistance; Intestine; Postprandial

Indexed keywords

CHYLOMICRON; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INSULIN; LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PIOGLITAZONE; TRIACYLGLYCEROL;

DOWN REGULATION; FATTY ACID BLOOD LEVEL; GASTROINTESTINAL ABSORPTION; HUMAN; INSULIN RESISTANCE; LIPID ABSORPTION; LIPID DIET; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINE; UPREGULATION;

ANIMALS; FATTY ACIDS, NONESTERIFIED; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INSULIN RESISTANCE; INTESTINES; LIPOPROTEINS; LIVER; MODELS, ANIMAL;

ANIMALIA;

EID: 43249119219     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282ffaf82     Document Type: Review

References (66)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. Lewis GF, Steiner G. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 1996; 12:37-56.
3. Lamarche B, Lewis GF. Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol. Can J Cardiol 1998; 14:841-851.
4. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106:453-458.
5. Ohnishi H, SaitohS, Takagi S, et al. Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis 2002; 164:167-170.
6. Saito M, Eto M, Kaku K. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes. Metabolism 2002; 51:964-969.
7. Schaefer EJ, McNamara JR, Shah PK, et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002; 25:989-994.
8. Higashi K, Ito T, Nakajima K, et al. Remnant-like particles cholesterol is higher in diabetic patients with coronary artery disease. Metabolism 2001; 50:1462-1465.
9. Taniguchi A, Fukushima M, Sakai M, et al. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 2000; 23:1766-1769.
10. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001; 154:229-236.
11. Mero N, Malmstrom R, Steiner G, et al. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000; 150:167-177.
12. Siddiqi SA, Mahan J, Siddiqi S, et al. Vesicle-associated membrane protein 7 is expressed in intestinal ER. J Cell Sci 2006; 119:943-950.
13. Siddiqi SA, Siddiqi S, Mahan J, et al. The identification of a novel endoplasmic reticulum to Golgi SNARE complex used by the prechylomicron transport vesicle. J Biol Chem 2006; 281:20974-20982.
14. Neeli I, Siddiqi SA, Siddiqi S, et al. Liver fatty acid-binding protein initiates budding of prechylomicron transport vesicles from intestinal endoplasmic reticulum. J Biol Chem 2007; 282:17974-17984. Liver FABP appears to play an important role in the formation and function of PCTV and the initiation of chylomicron assembly.
15. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000; 148:1-15.
16. Cartwright IJ, Plonne D, Higgins JA. Intracellular events in the assembly of chylomicrons in rabbit enterocytes. J Lipid Res 2000; 41:1728-1739.
17. Kumar NS, Mansbach CM 2nd. Prechylomicron transport vesicle: isolation and partial characterization. Am J Physiol 1999; 276:G378-G386.
18. Siddiqi SA, Gorelick FS, Mahan JT, Mansbach CM 2nd. COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the prechylomicron transport vesicle. J Cell Sci 2003; 116:415-427.
19. Levy E, Stan S, Delvin E, et al. Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. J Biol Chem 2002; 277:16470-16477.
20. Jones B, Jones EL, Bonney SA, et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet 2003; 34:29-31.
21. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006; 17:238-246.
22. Cohn JS. Postprandial lipemia and remnant lipoproteins. Clin Lab Med 2006; 26:773-786.
23. Arbeeny CM, Meyers DS, Bergquist KE, Gregg RE. Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster. J Lipid Res 1992; 33:843-851.
24. Liu GL, Fan LM, Redinger RN. The association of hepatic apoprotein and lipid metabolism in hamsters and rats. Comp Biochem Physiol A 1991; 99:223-228.
25. Taghibiglou C, Rudy D, Van Iderstine SC, et al. Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes. J Lipid Res 2000; 41:499-513.
26. Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275:8416-8425.
27. Leung N, Naples M, Uffelman K, et al. Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance. Atherosclerosis 2004; 174:235-241.
28. Haidari M, Leung N, Mahbub F, et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB-48-containing lipoprotein overproduction. J Biol Chem 2002; 277:31646-31655.
29. Lewis GF, Uffelman K, Naples M, et al. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology 2005; 146:247-255.
30. Lewis GF, Naples M, Uffelman K, et al. Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin-sensitized Syrian golden hamsters. Endocrinology 2004; 145:5006-5012.
31. Risser TR, Reaven GM, Reaven EP. Intestinal very low density lipoprotein secretion in insulin-deficient rats. Diabetes 1978; 27:902-908.
32. Stifel FB, Herman RH, Rosensweig NS. Dietary regulation of glycolytic enzymes. 3. Adaptive changes in rat jejunal pyruvate kinase, phosphofructokinase, fructosediphosphatase and glycerol-3-phosphate dehydrogenase. Biochim Biophys Acta 1969; 184:29-34.
33. Field FJ, Born E, Murthy S, Mathur SN. Regulation of sterol regulatory element-binding proteins by cholesterol flux in CaCo-2 cells. J Lipid Res 2001; 42:1687-1698.
34. Field FJ, Born E, Murthy S, Mathur SN. Polyunsaturated fatty acids decrease the expression of sterol regulatory element-binding protein-1 in CaCo-2 cells: effect on fatty acid synthesis and triacylglycerol transport. Biochem J 2002; 368:855-864.
35. Field FJ, Born E, Mathur SN. Fatty acid flux suppresses fatty acid synthesis in hamster intestine independently of SREBP-1 expression. J Lipid Res 2003; 44:1199-1208.
36. Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 2006; 55:1316-1326.
37. Zoltowska M, Ziv E, Delvin E, et al. Both insulin resistance and diabetes in Psammomys obesus upregulate the hepatic machinery involved in intracellular VLDL assembly. Arterioscler Thromb Vasc Biol 2004; 24:118-123.
38. Zoltowska M, Ziv E, Delvin E, et al. Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes. Diabetes 2003; 52:2539-2545.
39. Shafrir E, Ziv E, Kalman R. Nutritionally induced diabetes in desert rodents as models of type 2 diabetes: Acomys cahirinus (spiny mice) and Psammomys obesus (desert gerbil). Ilar J 2006; 47:212-224.
40. Levy E, Spahis S, Ziv E, et al. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia 2006; 49:1937-1945.
41. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007; 190:282-290. This important recent report shows substantial intestinal dysfunction in the insulin-resistant JCR-LA-cp rat model including enhanced lipid absorption and increased lymph apoB-48 levels.
42. Lally S, Owens D, Tomkin GH. Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats. Metabolism 2007; 56:430-438.
43. Lally S, Owens D, Tomkin GH. The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating postprandial lipoproteins in diabetes. Atherosclerosis 2007; 193:343-351.
44. Sasase T, Morinaga H, Yamamoto H, et al. Increased fat absorption and impaired fat clearance cause postprandial hypertriglyceridemia in Spontaneously Diabetic Torii rat. Diabetes Res Clin Pract 2007; 78:8-15. The authors provide evidence for increased fat absorption in a diabetic animal model, suggesting a link between diabetes and efficiency of intestinal fat absorption and chylomicron production.
45. Qin B, Qiu W, Avramoglu RK, Adeli K. Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes 2007; 56:450-461. TNF-α infusion was found to directly stimulate lipoprotein secretion and intestinal insulin resistance in the hamster. These data appear to clearly suggest that increased inflammatory factors may play an important role in dysregulation of intestinal insulin signaling and lipoprotein metabolism.
46. Duez H, Lamarche B, Uffelman KD, et al. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006; 26:1357-1363.
47. Hogue JC, Lamarche B, Tremblay AJ, et al. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res 2007; 48:1336-1342. This study showed direct evidence in humans for increased production rate of apoB-48-chylomicrons, confirming similar observations made in animal models of insulin resistance and diabetes.
48. Duez H, Lamarche B, Uffelman KD, et al. Dissociation between the insulin sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J Clin Endocrinol Metab 2008; 19 Feb [Epub ahead of print].
49. Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 2005; 19:625-635.
50. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23:201-229.
51. Steiner G, Poapst M, Davidson JK. Production of chylomicron-like lipoproteins from endogenous lipid by the intestine and liver of diabetic dogs. Diabetes 1975; 24:263-271.
52. Duez H, Lamarche B, Valero R, et al. Intestinal as well as hepatic lipoprotein production is stimulated by an acute elevation of plasma FFAs in humans. Circulation (in press). In this study that employed stable isotope enrichment of apolipoproteins and multicompartmental kinetic modeling the authors demonstrated, for the first time in humans, that intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids. This observation confirms that the production of intestinal triglyceride-rich lipoproteins is regulated by fatty acids derived from the circulation and provides one potential mechanism for the increased production rate of these lipoproteins in insulin-resistant states.
53. Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995; 95:158-166.
54. Guo Q, Avramoglu RK, Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 2005; 54:689-697.
55. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117:13-23.
56. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006; 27:719-727.
57. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr 2006; 26:391-411.
58. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157.
59. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-165.
60. Thomsen C, Rasmussen O, Lousen T, et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 1999; 69:1135-1143.
61. Bulotta A, Perfetti R, Hui H, Boros LG. GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release. J Lipid Res 2003; 44:1559-1565.
62. Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of nonesterified fatty acids in humans. Diabetologia 2006; 49:452-458.
63. Qin X, Shen H, Liu M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288:G943-G949.
64. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49:2049-2057.
65. Hirotani Y, Ikeda T, Ikeda K, et al. Effects of Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) on intestinal function in streptozotocin-induced diabetic rats. Yakugaku Zasshi 2007; 127:1509-1513.
66. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006; 130:44-54.